Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05133-y
Abstract: BackgroundSeveral trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first or subsequent lines of therapy. However, due to the lack of direct/indirect comparisons,… read more here.
Keywords: palbociclib; palbociclib ribociclib; ribociclib abemaciclib; analysis ... See more keywords
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-020-00930-x
Abstract: Palbociclib, ribociclib, and abemaciclib are inhibitors of the cyclin-dependent kinases 4 and 6 approved for the treatment of locally advanced or metastatic breast cancer. In this review, we provide an overview of the available clinical… read more here.
Keywords: clinical pharmacokinetics; cyclin dependent; palbociclib ribociclib; ribociclib abemaciclib ... See more keywords
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.03.064
Abstract: The role of cyclin-dependent kinases (CDKs) in regulating the transition of cell cycle steps makes this class of enzymes a suitable target for cancer therapy. Three different generations of CDKs inhibitors have been developed so… read more here.
Keywords: palbociclib ribociclib; ribociclib abemaciclib; chemistry; generation cdk ... See more keywords